Skip to content

Research on the establishment and clinical application of pancreatic cancer based on magnetic resonance imaging

Research on the establishment and clinical application of pancreatic cancer based on magnetic resonance imaging

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096492
Enrollment
Unknown
Registered
2025-01-24
Start date
2023-12-28
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Group:MRI guided adaptive radiotherapy

Sponsors

Peking Union Medical College Hospital, Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1: Age =18 years 2: ECOG =2 3: The diagnosis of pancreatic malignant tumor was confirmed by histology or cytology 4: Has the pancreatic tumor radiotherapy indication 5: Blood routine test and liver and kidney function meet the conditions for radiotherapy 6: Informed consent

Exclusion criteria

Exclusion criteria: 1: Medical/psychological contraindications for Magnetic Resonance Imaging (MRI) 2: The patient's physical condition makes it difficult to complete the process of MRI-guided radiotherapy 3: The area to be irradiated in this radiotherapy session has previously undergone radiotherapy 4: The patient is currently participating in other clinical studies that may impact the results of this study (determined by the principal investigator) 5: Severe illnesses that may significantly affect compliance with the clinical trial, such as unstable heart disease requiring treatment, renal disease, chronic hepatitis, uncontrolled diabetes, mental illness, etc. 6: Other situations deemed unsuitable for participation in this clinical study by the investigator

Design outcomes

Primary

MeasureTime frame
Incidence of complications;Local tumor control rate;Progression-Free Survival Rate;

Secondary

MeasureTime frame
Overall survival rate;Function MR and Therapeutic Response;

Countries

China

Contacts

Public ContactLian Xin

Peking Union Medical College Hospital, Peking Union Medical College

lian.xin@126.com+86 186 0005 2995

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026